ALNY NASDAQ
Alnylam Pharmaceuticals, Inc.
1W: -2.4%
1M: -11.1%
3M: -21.1%
YTD: -43.1%
1Y: -50.9%
3Y: +41.8%
5Y: +11.7%
$226.79
-0.87 (-0.38%)
After Hours: $226.09 (-0.70, -0.31%)
Weekly Expected Move ±5.6%
$199
$211
$224
$237
$249
Credit Risk of going bust: lower than 72% of companies Debt: 4.0% of company value Bonds: $81.8M held by 45 funds → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.82 (down 99.6%), Alnylam Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $1.27B against a stock market value of $30.46B.
Distance to default 7.98 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $505.5M (short-term plus half of long-term), stock volatility 51.3%; Altman Z'' 1.62. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $0.82 (down 99.6%), Alnylam Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $1.27B against a stock market value of $30.46B.
Distance to default 7.98 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $505.5M (short-term plus half of long-term), stock volatility 51.3%; Altman Z'' 1.62. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Revenue Segmentation
By Product / Service
By Geography
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$3.7B
+65.2% ▲
5Y CAGR: +49.8%
Gross Profit
$3.0B
+57.8% ▲
5Y CAGR: +48.9%
Operating Income
$502M
+383.6% ▲
Net Income
$314M
+212.8% ▲
EPS (Diluted)
$2.33
+206.9% ▲
EBITDA
$557M
+411.6% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $844M | $1.0B | $1.8B | $2.2B | $3.7B |
| YoY Growth | +71.3% | +22.9% | +76.2% | +23.0% | +65.2% |
| Cost of Revenue | $140M | $169M | $310M | $323M | $677M |
| Gross Profit | $704M | $869M | $1.5B | $1.9B | $3.0B |
| Gross Margin | 83.4% | 83.7% | 83.0% | 85.6% | 81.8% |
| R&D Expenses | $792M | $883M | $1.0B | $1.1B | $1.3B |
| SG&A Expenses | $621M | $771M | $796M | $976M | $1.2B |
| Operating Expenses | $1.4B | $1.7B | $1.8B | $2.1B | $2.5B |
| Operating Income | -$709M | -$785M | -$282M | -$177M | $502M |
| Operating Margin | -83.9% | -75.7% | -15.4% | -7.9% | 13.5% |
| Interest Expense | $143M | $156M | $121M | $142M | $253M |
| Income Before Tax | -$852M | -$1.1B | -$434M | -$377M | $323M |
| Tax Expense | $680K | $4M | $7M | -$99M | $9M |
| Net Income | -$853M | -$1.1B | -$440M | -$278M | $314M |
| Net Margin | -101.0% | -109.0% | -24.1% | -12.4% | 8.4% |
| EPS (Diluted) | $-7.20 | $-9.30 | $-3.52 | $-2.18 | $2.33 |
| EBITDA | -$662M | -$927M | -$258M | -$179M | $557M |
| Shares Outstanding | 118M | 122M | 125M | 128M | 135M |